• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Reporting bias in trials of volume resuscitation with hydroxyethyl starch.羟乙基淀粉容量复苏试验中的报告偏倚。
Wien Klin Wochenschr. 2014 Apr;126(7-8):189-94. doi: 10.1007/s00508-014-0503-y. Epub 2014 Mar 5.
2
Fluid resuscitation with hydroxyethyl starches in patients with sepsis is associated with an increased incidence of acute kidney injury and use of renal replacement therapy: a systematic review and meta-analysis of the literature.脓毒症患者使用羟乙基淀粉进行液体复苏与急性肾损伤发生率增加及肾脏替代治疗的使用相关：一项文献系统综述和荟萃分析
J Crit Care. 2014 Feb;29(1):185.e1-7. doi: 10.1016/j.jcrc.2013.09.031. Epub 2013 Oct 22.
3
Fluid resuscitation with 6% hydroxyethyl starch (130/0.4) in acutely ill patients: an updated systematic review and meta-analysis.急性病患者中用 6%羟乙基淀粉（130/0.4）进行液体复苏：一项更新的系统评价和荟萃分析。
Anesth Analg. 2012 Jan;114(1):159-69. doi: 10.1213/ANE.0b013e318236b4d6.
4
Hydroxyethyl starch for fluid resuscitation in critically ill patients.羟乙基淀粉在危重症患者液体复苏中的应用。
Can J Anaesth. 2013 Jul;60(7):709-13. doi: 10.1007/s12630-013-9936-4. Epub 2013 Apr 20.
5
Fluid therapy in critical illness: a special focus on indication, the use of hydroxyethyl starch and its different raw materials.危重病患者的液体治疗：特别关注适应证、羟乙基淀粉的使用及其不同原料。
Curr Opin Anaesthesiol. 2013 Jun;26(3):253-60. doi: 10.1097/ACO.0b013e3283606b71.
6
Acute kidney injury with hydroxyethyl starch 130/0.42 in severe sepsis.严重脓毒症中使用羟乙基淀粉130/0.42导致的急性肾损伤
Acta Anaesthesiol Scand. 2015 Mar;59(3):329-36. doi: 10.1111/aas.12453. Epub 2014 Dec 18.
7
Resuscitation with hydroxyethyl starch improves renal function and lactate clearance in penetrating trauma in a randomized controlled study: the FIRST trial (Fluids in Resuscitation of Severe Trauma).一项随机对照研究：FIRST 试验（严重创伤复苏中的液体）表明羟乙基淀粉复苏可改善穿透性创伤患者的肾功能和乳酸清除率。
Br J Anaesth. 2011 Nov;107(5):693-702. doi: 10.1093/bja/aer229. Epub 2011 Aug 19.
8
Fluid replacement with hydroxyethyl starch in critical care--a reassessment.危重病患者羟乙基淀粉的液体替代治疗——再评估。
Dtsch Arztebl Int. 2013 Jun;110(26):443-50. doi: 10.3238/arztebl.2013.0443. Epub 2013 Jun 28.
9
Hydroxyethyl starch for resuscitation.羟乙基淀粉复苏。
Curr Opin Crit Care. 2013 Aug;19(4):321-5. doi: 10.1097/MCC.0b013e3283632de6.
10
Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis.羟乙基淀粉给药与需要容量复苏的危重症患者死亡率和急性肾损伤的关系：系统评价和荟萃分析。
JAMA. 2013 Feb 20;309(7):678-88. doi: 10.1001/jama.2013.430.

引用本文的文献

1
Conservative fluid resuscitation protocol does not reduce the incidence of reoperation for bleeding after emergency CABG.保守液体复苏方案不会降低急诊 CABG 后再次出血行手术的发生率。
Sci Rep. 2024 Sep 9;14(1):21037. doi: 10.1038/s41598-024-71028-8.
2
Understanding the Harms of HES: A Review of the Evidence to Date.了解羟乙基淀粉的危害：迄今为止的证据综述。
Turk J Anaesthesiol Reanim. 2019 Apr;47(2):81-91. doi: 10.5152/TJAR.2019.72681. Epub 2019 Jan 29.
3
Acute kidney injury in critically burned patients treated with hydroxyethyl starch: a response to Sánchez-Sánchez et al.接受羟乙基淀粉治疗的严重烧伤患者的急性肾损伤：对桑切斯 - 桑切斯等人的回应
Ann Burns Fire Disasters. 2017 Sep 30;30(3):220-221.
4
Comparison of hydroxyethyl starch regulatory summaries from the Food and Drug Administration and the European Medicines Agency.美国食品药品监督管理局与欧洲药品管理局对羟乙基淀粉监管概述的比较。
J Pharm Policy Pract. 2017 Mar 21;10:12. doi: 10.1186/s40545-016-0090-6. eCollection 2017.
5
Resuscitation with polymeric plasma substitutes is permissive for systemic inflammatory response syndrome and sepsis in multiply injured patients: a retrospective cohort study.多部位创伤患者应用聚合型血浆代用品复苏可导致全身炎症反应综合征和脓毒症：一项回顾性队列研究。
Eur J Med Res. 2016 Oct 13;21(1):39. doi: 10.1186/s40001-016-0227-8.
6
Beautiful small: Misleading large randomized controlled trials? The example of colloids for volume resuscitation.美好却微小：误导性的大型随机对照试验？以胶体用于容量复苏为例
J Anaesthesiol Clin Pharmacol. 2015 Jul-Sep;31(3):394-400. doi: 10.4103/0970-9185.161680.
7
Concerns over use of hydroxyethyl starch solutions.对羟乙基淀粉溶液使用的担忧。
BMJ. 2014 Nov 10;349:g5981. doi: 10.1136/bmj.g5981.

本文引用的文献

1
Hydroxyethyl starch-induced pruritus: clinical characteristics and influence of dose, molecular weight and substitution.羟乙基淀粉诱导的瘙痒：临床特征及剂量、分子量和取代度的影响
Acta Derm Venereol. 2014 May;94(3):282-7. doi: 10.2340/00015555-1639.
2
Hydroxyethyl starch - the importance of being earnest.羟乙基淀粉——认真的重要性。
Scand J Trauma Resusc Emerg Med. 2013 Aug 9;21:61. doi: 10.1186/1757-7241-21-61.
3
[Limited applications for hydroxyethyl starch : background and alternative concepts].[羟乙基淀粉的应用受限：背景及替代概念]
Anaesthesist. 2013 Aug;62(8):644-55. doi: 10.1007/s00101-013-2220-8.
4
Concerns about renal safety of HES 130.对130/0.4羟乙基淀粉（HES 130）肾脏安全性的担忧。
Crit Care. 2013 Aug 1;17(4):444. doi: 10.1186/cc12805.
5
Re-evaluating currently available data and suggestions for planning randomised controlled studies regarding the use of hydroxyethyl starch in critically ill patients - a multidisciplinary statement.关于羟乙基淀粉在危重症患者中应用的随机对照研究规划，重新评估现有数据及建议——一份多学科声明
Crit Care. 2013 Jul 26;17(4):R166. doi: 10.1186/cc12845.
6
Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function.羟乙基淀粉（HES）与其他液体疗法：对肾功能的影响。
Cochrane Database Syst Rev. 2013 Jul 23;2013(7):CD007594. doi: 10.1002/14651858.CD007594.pub3.
7
Randomised trials of 6% tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: systematic review and meta-analysis.严重脓毒症 6% 琥珀明胶（羟乙基淀粉 130/0.4 或 0.42）随机试验报告死亡率：系统评价和荟萃分析。
Intensive Care Med. 2013 May;39(5):811-22. doi: 10.1007/s00134-013-2863-6. Epub 2013 Feb 22.
8
Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis.羟乙基淀粉给药与需要容量复苏的危重症患者死亡率和急性肾损伤的关系：系统评价和荟萃分析。
JAMA. 2013 Feb 20;309(7):678-88. doi: 10.1001/jama.2013.430.
9
Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis.羟乙基淀粉 130/0.38-0.45 与晶体或白蛋白在脓毒症患者中的比较：系统评价与荟萃分析和试验序贯分析。
BMJ. 2013 Feb 15;346:f839. doi: 10.1136/bmj.f839.
10
Fluid resuscitation with 6 % hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy.急性病患者中用 6%羟乙基淀粉（130/0.4 和 130/0.42）进行液体复苏：对死亡率和肾脏替代治疗影响的系统评价。
Intensive Care Med. 2013 Apr;39(4):558-68. doi: 10.1007/s00134-013-2840-0. Epub 2013 Feb 14.

羟乙基淀粉容量复苏试验中的报告偏倚。

Reporting bias in trials of volume resuscitation with hydroxyethyl starch.

作者信息

Wiedermann Christian J

机构信息

Academic Teaching Department of Internal Medicine, Central Hospital of Bozen/Bolzano, Lorenz-Böhler-Street 5, 39100, Bozen/Bolzano (BZ), Italy,

出版信息

Wien Klin Wochenschr. 2014 Apr;126(7-8):189-94. doi: 10.1007/s00508-014-0503-y. Epub 2014 Mar 5.

DOI:10.1007/s00508-014-0503-y
PMID:24596076
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3997826/
Abstract

The possibility of renal damage by hydroxyethyl starch has become the focus of intensive dispute based on the findings of published large trials. The aim of this narrative review is to analyze outcome reporting bias in the literature on volume resuscitation, focusing on selective outcome reporting in published randomized and observational trials with "modern" hydroxyethyl starch as therapeutic intervention. Three recent publications claimed to confirm renal safety of hydroxyethyl starch 130/0.4 for indications in severe sepsis, trauma, and critical illness, respectively. Selective outcome reporting was identified in these studies including underreporting of side effects and change of primary study outcomes. In conclusion, selective outcome reporting bias is identified in recent publications of clinical trials on volume resuscitation with HES.

摘要

基于已发表的大型试验结果，羟乙基淀粉导致肾损伤的可能性已成为激烈争论的焦点。本叙述性综述的目的是分析容量复苏文献中的结果报告偏倚，重点关注以“现代”羟乙基淀粉作为治疗干预措施的已发表随机试验和观察性试验中的选择性结果报告。最近有三篇出版物分别声称证实了羟乙基淀粉130/0.4在严重脓毒症、创伤和危重病适应症中的肾脏安全性。在这些研究中发现了选择性结果报告，包括副作用报告不足和主要研究结果的改变。总之，在最近关于使用羟乙基淀粉进行容量复苏的临床试验出版物中发现了选择性结果报告偏倚。